5. 1), hvori 20. 536 patienter blev behandlet med enten < Zocord > 40 mg/ dag (n = 10. 269) eller placebo (n = 10. 267), var sikkerhedsprofilerne sammenlignelige mellem patienter behandlet med < Zocord > 40 mg og patienter behandlet med placebo over undersøgelsens gennemsnitlige 5 år.
In HPS (see section 5.1) involving 20,536 patients treated with 40 mg/ day of< Zocord > (n = 10,269) or placebo (n = 10,267), the safety pr ofiles were comparable between patients treated with < Zocord > 40 mg and patients treated with placebo over the mean 5 years of the study.